Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone ophthalmic - Allergan

Drug Profile

Dexamethasone ophthalmic - Allergan

Alternative Names: DEX implant; DEX PS DDS; Dexamethasone implant; Dexamethasone posterior segment drug delivery system; Ozurdex; Posurdex; SK-0503

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan
  • Developer Allergan; Johns Hopkins University; Sanwa Kagaku Kenkyusho
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic macular oedema; Retinal oedema; Uveitis
  • Phase II/III Retinal vein occlusion
  • No development reported Age-related macular degeneration

Most Recent Events

  • 22 Mar 2018 Launched for Retinal oedema in China (Intravitreous)
  • 30 Oct 2017 Registered for Retinal oedema in China (Intravitreous)
  • 05 Jun 2017 Jaeb Center for Health Research, in collaboration with Allergan and Genentech, completes a phase II trial in Diabetic macular oedema (Combination therapy) in USA (Intravitreous) (NCT01945866)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top